Document Detail

A randomized trial comparing oral misoprostol with intra-amniotic prostaglandin F2alpha for second trimester terminations.
MedLine Citation:
PMID:  16529667     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To compare the efficacy of oral misoprostol with that of intra-amniotic prostaglandin F2alpha (PGF2alpha) for second trimester pregnancy termination. METHODS: One hundred seventeen women with pregnancies of between 16 and 22 weeks' gestation were randomly assigned after insertion of laminaria to receive either oral misoprostol 400 microg every 4 hours (to a maximum of four doses) or intra-amniotic PGF2alpha 40 mg. The rate of complete abortion within 24 hours was the primary outcome for power analysis. Secondary outcome measures were the rate of dilatation and curettage (D&C) for retained placenta and the rates of fever and gastrointestinal complications. RESULTS: Patient characteristics were similar in both groups. The rate of complete abortion within 24 hours was similar in the misoprostol (63%) and PGF2alpha (66%) groups. The rate of retained placenta requiring D&C was significantly greater in the PGF2alpha group (22.4% vs. 3.4%, P = 0.002). There were no differences in other maternal morbidities. Parous patients treated with oral misoprostol had a significantly greater rate of complete abortion than nulliparous patients (84% vs. 57%, P = 0.04). CONCLUSIONS: Oral misoprostol is as effective as intra-amniotic PGF2alpha for second trimester pregnancy termination when laminaria is inserted before treatment. Parous patients have a higher success rate than nulliparous patients with use of oral misoprostol. Oral misoprostol is associated with a very low rate of placental retention.
Gerald P Marquette; M Amanda Skoll; Lorraine Dontigny
Related Documents :
8332657 - Psychiatric outcome of termination of pregnancy for foetal abnormality.
16529667 - A randomized trial comparing oral misoprostol with intra-amniotic prostaglandin f2alpha...
9131497 - Intraamniotic prostaglandin f2 alpha for pregnancy termination in the second and early ...
20303487 - Septic shock due to klebsiella pneumoniae after medical abortion with misoprostol-only ...
9866067 - Low blastocyst formation rates in day-2 fertilized oocytes.
17943767 - Cleavage stage versus blastocyst stage embryo transfer in assisted conception.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstétrique et gynécologie du Canada : JOGC     Volume:  27     ISSN:  1701-2163     ISO Abbreviation:  J Obstet Gynaecol Can     Publication Date:  2005 Nov 
Date Detail:
Created Date:  2006-03-13     Completed Date:  2006-05-09     Revised Date:  2007-06-29    
Medline Journal Info:
Nlm Unique ID:  101126664     Medline TA:  J Obstet Gynaecol Can     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  1013-8     Citation Subset:  IM    
University of British Columbia, British Columbia Women's Hospital and Health Centre, Vancouver, BC.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abortifacient Agents, Nonsteroidal / standards*
Abortion, Induced*
Administration, Oral
Amniotic Fluid
Dinoprost / standards*
Misoprostol / standards*
Placenta, Retained / epidemiology
Pregnancy Trimester, Second
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Abortifacient Agents, Nonsteroidal; 551-11-1/Dinoprost; 59122-46-2/Misoprostol
Comment In:
J Obstet Gynaecol Can. 2006 Mar;28(3):189; author reply 190   [PMID:  16650352 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Group B streptococcal testing during pregnancy: survey of postpartum women and audit of current pren...
Next Document:  Abrupt discontinuation of psychotropic drugs following confirmation of pregnancy: a risky practice.